Realbotix LLC, the pending acquisition target of Onconetix, Inc. (NASDAQ: ONCO), has launched a pilot program with an unidentified European telecommunications company to deploy humanoid robots in live presentations and events, according to a statement from Onconetix.

The pilot is designed to test how Realbotix robots can function as presenters, hosts, and brand ambassadors in audience-facing environments, moving beyond one-on-one interactions to settings involving larger groups. Potential roles identified for the robots include corporate event hosting, live product demonstrations, customer engagement, education and training support, hospitality and retail assistance, public information services, reception and concierge functions, and guided visitor experiences.

The program will also evaluate how the Realbotix platform can be configured to match a partner's specific workflows.

Onconetix entered into a definitive share exchange agreement on Feb. 12, 2026, to acquire 100% of the equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT), in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

Onconetix is currently a commercial-stage biotechnology company focused on oncology and owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union.